Supply chain disruptions and manufacturing shortages have significantly affected the clinical trial industry, an issue exacerbated by an unprecedented demand for clinical trial kits. To help maintain business continuity, the Labcorp Central Laboratories team had to develop creative operational solutions at every step of production and quickly accelerate the launch …
Technologies, tools and processes to support patient-centric oncology trials
There is a gap between the number of patients needed to participate in new cancer trials and the number who give consent to take part. Decentralized clinical trials (DCTs) are helping to address this gap by increasing the reach of clinical studies beyond conventional research sites. DCTs provide an opportunity …
Connecting diagnostic and drug development expertise around the world: Meet Claudine
As the drug development and diagnostic businesses of Labcorp strengthen their combined capabilities, Claudine Rigal, PharmD, Clinical Biologist, Head of Asia Pacific Laboratory Operations and Global Head of Anatomic Pathology Operations for Labcorp Drug Development, is excited about the opportunity to improve service delivery for biotech and pharma clients. We …
Addressing Challenges with Ulcerative Colitis Clinical Study Recruitment
We understand the significant challenges sponsors face with patient recruitment in their ulcerative colitis (UC) clinical studies. While the prevalence of UC is relatively high (~0.2% in North America, Oceania and much of Europe – and rising in urbanized/industrialized countries in Africa, Asia and Latin America1), recruitment rates into clinical …
Enhancing the Investigator Site Experience with Electronic Query Notification and Resolution (eQuery)
Investigator sites provide an essential connection between drug development sponsors and patients in clinical trials—and play a key role in producing high-quality data. To better support a site’s day-to-day study activities and make a difference for patient care, Labcorp Central Laboratory Services (CLS) is continually evaluating current practices and implementing …
Cell & Gene Therapy Answers: The Evolving Cell & Gene Therapy Landscape
Your source for answers to the complex challenges of cell and gene therapy development. We recently sat down with Maryland Franklin, Vice President and Enterprise Head of Cell & Gene Therapy at Labcorp Drug Development, to discuss key considerations for developing cell or gene therapies in today’s quickly expanding pipeline.
The July 2021 edition of the Labcorp Drug Development Decentralized Clinical Trials blog
In our previous edition of the blog, we highlighted our upcoming presence at DIA. Our focus at the show this year was patient diversity, patient equity, and patient engagement. The recordings from the show are now available, so this month we will point you toward those in case you missed …
Risk Library: A Proactive Approach to Risk Management for Clinical Studies
Categorizing and centralizing cross-study, cross-functional risk data As part of our Xcellerate® technology suite, we developed a risk library based on cross-functional input identifying the most common risks to our clinical studies, regardless of clinical phase. These common study risks became the foundation of the risk library available to users …
Decentralized Clinical Trials (DCT) Monthly Blog – May 2021
This month in the DCT Blog, we are going to put the spotlight on several events coming up in the next few weeks.
Five Benefits of Risk-Based Quality Management (RBQM) for Clinical Trial Data
Risk-based quality management methodologies address risk control and management during execution of a clinical trial. RBQM adoption has generated valuable benefits for project management and clinical operations, changing the way trial monitoring is done. However, data management activities are ideally suited for an RBQM approach as well. Today, we explore …